{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:31:56Z","timestamp":1790386316016,"version":"4.1.0"},"reference-count":43,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.3201\/eid3006.230975","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:01:25Z","timestamp":1716303685000},"source":"Crossref","is-referenced-by-count":12,"title":["Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark"],"prefix":"10.3201","volume":"30","author":[{"given":"Katrine Finderup","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Birk","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Dalby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikke Kristensen","family":"Lomholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christian","family":"Slotved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Fuursted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitta Barrella","family":"Harboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Sv\u00e6rke","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle","family":"Valentiner-Branth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3006.230975-202405131522-R1","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/cid\/ciu524","article-title":"Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.","volume":"59","author":"Harboe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R2","unstructured":"Statens Serum Institut. PCV coverage and invasive pneumococcal disease 2011. EPI-NEWS No. 21\u20142012 [cited 20 Nov 2023]. https:\/\/en.ssi.dk\/news\/epi-news\/2012\/no-21---2012"},{"key":"key-10.3201\/eid3006.230975-202405131522-R3","unstructured":"Centers for Disease Control and Prevention. Pneumococcal disease: risk factors and how it spreads. 2022 Jul 28 [cited 2023 Apr 26]. https:\/\/www.cdc.gov\/pneumococcal\/about\/risk-transmission.html"},{"key":"key-10.3201\/eid3006.230975-202405131522-R4","unstructured":"Statens Serum Institut. Pneumococcal disease\u2014risk groups [in Norwegian] [cited 2022 Mar 11]. https:\/\/www.ssi.dk\/vaccinationer\/risikogrupper\/invasiv-pneumokoksygdom\/pneumokok-risikogrupper"},{"key":"key-10.3201\/eid3006.230975-202405131522-R5","unstructured":"Centers for Disease Control and Prevention. COVID-19 risks and information for older adults. 2023 Feb 22 [cited 2023 Apr 26]. https:\/\/www.cdc.gov\/aging\/covid19\/index.html"},{"key":"key-10.3201\/eid3006.230975-202405131522-R6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12879-020-05717-w","article-title":"First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study.","volume":"21","author":"Holler","year":"2021","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R7","unstructured":"Indenrigs- og Sundhedsministeriet. Bekendtg\u00f8relse om gratis vaccination mod influenza, pneumokokker og COVID-19 til visse persongrupper. 2022 Sep 9 [cited 2024 Feb 17]. https:\/\/www.retsinformation.dk\/eli\/lta\/2022\/1260"},{"key":"key-10.3201\/eid3006.230975-202405131522-R8","unstructured":"Statens Serum Institut. Extension of the invasive pneumococcal disease vaccination programme. Tuberculosis in 2019\u201320. 2022 Feb 4 [cited 2024 Apr 29]. https:\/\/en.ssi.dk\/news\/epi-news\/2021\/no-49-50---2021"},{"key":"key-10.3201\/eid3006.230975-202405131522-R9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10096-022-04513-5","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals\u2009\u2265\u200965\u00a0years of age: a Danish cohort study.","volume":"41","author":"Nielsen","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1086\/429236","article-title":"Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.","volume":"40","author":"Dominguez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R11","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3006.230975-202405131522-R12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales.","volume":"6","author":"Djennad","year":"2019","journal-title":"EClinicalMedicine"},{"key":"key-10.3201\/eid3006.230975-202405131522-R13","doi-asserted-by":"publisher","first-page":"20922","DOI":"10.2807\/1560-7917.ES2014.19.40.20922","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011.","volume":"19","author":"Gutierrez Rodriguez","year":"2014","journal-title":"Euro Surveill"},{"key":"key-10.3201\/eid3006.230975-202405131522-R14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.trivac.2013.09.004","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006\u2013July 2012.","volume":"2","author":"Wright","year":"2013","journal-title":"Trials Vaccinol"},{"key":"key-10.3201\/eid3006.230975-202405131522-R15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12879-020-05721-0","article-title":"Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75\u2009years and older in Taiwan.","volume":"21","author":"Su","year":"2021","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records.","volume":"11","author":"Schmidt","year":"2019","journal-title":"Clin Epidemiol"},{"key":"key-10.3201\/eid3006.230975-202405131522-R17","doi-asserted-by":"publisher","first-page":"20155","DOI":"10.2807\/ese.17.17.20155-en","article-title":"The Danish vaccination register.","volume":"17","author":"Grove Krause","year":"2012","journal-title":"Euro Surveill"},{"key":"key-10.3201\/eid3006.230975-202405131522-R18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients.","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"key-10.3201\/eid3006.230975-202405131522-R20","doi-asserted-by":"publisher","first-page":"20667","DOI":"10.2807\/1560-7917.ES2014.19.1.20667","article-title":"The Danish Microbiology Database (MiBa) 2010 to 2013.","volume":"19","author":"Voldstedlund","year":"2014","journal-title":"Euro Surveill"},{"key":"key-10.3201\/eid3006.230975-202405131522-R21","unstructured":"Norwegian Institute of Public Health. Recommendations for the use of pneumococcal vaccine outside the child vaccination program in Norway [in Norwegian] [cited 2022 Oct 3]. https:\/\/www.fhi.no\/publ\/2015\/anbefalinger-for-bruk-av-pneumokokk"},{"key":"key-10.3201\/eid3006.230975-202405131522-R22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1086\/377736","article-title":"Recurrent invasive pneumococcal disease: a population-based assessment.","volume":"37","author":"King","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJM199111213252101","article-title":"The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.","volume":"325","author":"Shapiro","year":"1991","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3006.230975-202405131522-R24","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1016\/j.vaccine.2019.07.005","article-title":"Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up.","volume":"37","author":"MacIntyre","year":"2019","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3006.230975-202405131522-R25","doi-asserted-by":"publisher","first-page":"e1003326","DOI":"10.1371\/journal.pmed.1003326","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.","volume":"17","author":"Lawrence","year":"2020","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid3006.230975-202405131522-R26","doi-asserted-by":"publisher","first-page":"e0169368","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis.","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PLoS One"},{"key":"key-10.3201\/eid3006.230975-202405131522-R27","unstructured":"Statens Serum Institut. Pneumococci [cited 2022 Sep 28]. https:\/\/en.ssi.dk\/vaccination\/vaccination-of-risk-groups\/pneumococci"},{"key":"key-10.3201\/eid3006.230975-202405131522-R28","unstructured":"Danish Medicines Agency. Pneumovax. Summary of product characteristics [cited 2023 Jul 4]. https:\/\/produktresume.dk\/AppBuilder\/search?utf8=%E2%9C%93&id=&type=&q=pneumovax&button=S%C3%B8g"},{"key":"key-10.3201\/eid3006.230975-202405131522-R29","unstructured":"Centers for Disease Control and Prevention. About pneumococcal vaccine: for poviders. 2022 Sep 8 [cited 2022 Oct 6]. https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/about-vaccine.html"},{"key":"key-10.3201\/eid3006.230975-202405131522-R30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2334-10-73","article-title":"Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.","volume":"10","author":"Vila-Corcoles","year":"2010","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R31","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1056\/NEJMoa022678","article-title":"Effectiveness of pneumococcal polysaccharide vaccine in older adults.","volume":"348","author":"Jackson","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3006.230975-202405131522-R32","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/cid\/civ096","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged \u226565 years: a retrospective case-control study.","volume":"60","author":"Leventer-Roberts","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R33","doi-asserted-by":"publisher","first-page":"2168354","DOI":"10.1080\/20018525.2023.2168354","article-title":"Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis.","volume":"10","author":"Sikj\u00e6r","year":"2023","journal-title":"Eur Clin Respir J"},{"key":"key-10.3201\/eid3006.230975-202405131522-R34","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.lanepe.2021.100126","article-title":"Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study.","volume":"7","author":"Perniciaro","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"key-10.3201\/eid3006.230975-202405131522-R35","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.3201\/eid2610.191531","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013\u20132017.","volume":"26","author":"Shimbashi","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R37","unstructured":"Statens Serum Institut. EPI-NEWS No. 14\/16\u20142020. [cited 2023 Jul 18]. https:\/\/en.ssi.dk\/news\/epi-news\/2020\/no-14---2020"},{"key":"key-10.3201\/eid3006.230975-202405131522-R38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12879-021-06103-w","article-title":"Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 8 in Denmark.","volume":"21","author":"Hansen","year":"2021","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R39","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014\u20132018.","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3006.230975-202405131522-R40","unstructured":"European Medicines Agency. Prevenar 13. 2018 Sep 17 [cited 2023 Jun 16]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevenar-13"},{"key":"key-10.3201\/eid3006.230975-202405131522-R41","doi-asserted-by":"publisher","first-page":"e00198","DOI":"10.1016\/j.heliyon.2016.e00198","article-title":"The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination.","volume":"2","author":"Slotved","year":"2016","journal-title":"Heliyon"},{"key":"key-10.3201\/eid3006.230975-202405131522-R42","unstructured":"European Medicines Agency. Vaxneuvance. 2021 Oct 12 [cited 2023 Jul 5]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxneuvance"},{"key":"key-10.3201\/eid3006.230975-202405131522-R43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1183\/09031936.04.00063504","article-title":"Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.","volume":"23","author":"Christenson","year":"2004","journal-title":"Eur Respir J"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/6\/23-0975_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:38:01Z","timestamp":1732905481000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/6\/23-0975_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3006.230975","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}